CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has FDA-approved CASGEVY therapy and stronger financials, versus Editas Medicine, which focuses on in vivo gene editing but lacks FDA approval and has a weaker balance sheet. CRISPR Therapeutics is recommended as the better 2026 investment due to its commercial-stage advantage, stronger cash position, and lower financial risk, despite Editas offering potentially greater upside if successful.

05/31/2026, 12:11 PM • The Motley Fool

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

Neutrolis Inc., a clinical-stage biotech company focused on treating autoimmune and inflammatory diseases, announced the appointment of Caren Deardorf as Chief Business & Strategy Officer. Deardorf brings over 30 years of executive leadership experience in commercialization and product launches, previously serving as Chief Commercial & Strategy Officer at Editas Medicine, Magenta Therapeutics, and Ohana Biosciences. She will lead business development and commercial strategy as Neutrolis advances its NTR-1011 candidate following positive Phase 1a results.

04/15/2026, 2:00 PM • GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Editas Medicine reported Q4 2025 financial results with a net loss of $5.6 million ($0.06 per share), down from $45.4 million in Q4 2024. The company's lead candidate EDIT-401 demonstrated >90% mean LDL-C reduction in preclinical studies and remains on track for IND/CTA submission by mid-2026, with first-in-human trials in HeFH patients expected to begin later in 2026. The company maintains a strong cash position with runway into Q3 2027.

03/09/2026, 7:00 AM • GlobeNewswire

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends

The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.

01/22/2026, 4:56 AM • GlobeNewswire

Gene Therapies for Cancer Treatment Market Projects USD 238.77 Billion at 39.94% CAGR by 2034

The global gene therapies for cancer treatment market is expected to grow from $8.28 billion in 2024 to $238.77 billion by 2034, with a 39.94% CAGR. North America currently dominates the market, with CAR-T cell therapy leading market share and significant innovations driving growth.

11/17/2025, 10:00 AM • GlobeNewswire

Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

Healthcare companies are advancing precision medicine through gene therapy, AI diagnostics, and innovative treatments targeting age-related conditions, with several firms making significant breakthroughs in areas like longevity biotechnology and personalized care.

09/25/2025, 9:15 AM • Benzinga

Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider

The global gene editing market is projected to grow from USD 6.09 billion in 2024 to USD 15.46 billion by 2032, driven by CRISPR technology advances, therapeutic applications, and significant research funding, with North America leading market development.

09/02/2025, 6:00 AM • GlobeNewswire

2 Beaten-Down Stocks to Avoid

Two biotech companies, Editas Medicine and Sarepta Therapeutics, are experiencing severe challenges that make them unattractive investment options. Editas Medicine lacks marketable products and has a history of abandoned projects, while Sarepta Therapeutics is dealing with patient deaths related to its gene therapy treatment Elevidys.

06/27/2025, 8:15 AM • The Motley Fool